Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Effect of nandrolone decanoate (Deca-Durabolin) on the disease activity of female patients with systemic lupus erythematosus (1994)
    Springer
    Rheumatology international 13 (1994), S. 237-240 
    Details
    ISSN: 1437-160X
    Keywords: Deca-Durabolin ; Systemic lupus erythematosus ; Female patients ; Androgenic activity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The clinical efficacy and adverse effects of nandrolone decanoate (Deca-Durabolin) were investigated in a double-blind placebo-controlled multicentre study in female patients with systemic lupus erythematosus (SLE). The patients received 100 mg Deca-Durabolin or placebo once every 2 weeks for 3 months. At the end of the study, 36 patients (18 on placebo and 18 on Deca-Durabolin) were evaluated. Beneficial effects were observed on arthralgia, and/or arthritis and minor vasculitis. Possible beneficial effects were seen on polymyalgia, active SLE rash, oral and/or nasal ulcerations and pleural and pericardial pain in the Deca-Durabolin-treated patients. The overall clinical assessment score showed that Deca-Durabolin would influence the disease course by lowering significantly the disease activity score. However, this treatment is still hampered by adverse reactions such as voice alterations and hirsutism. Therefore, the development of androgen-derived steroids free from androgenic activity should be encouraged, since these compounds may contribute to a new therapeutic modality in female SLE patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00290201
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    A high dose (up to 200 mg) tolerance and efficacy study of intra-articular rimexolone (Org 6216) in rheumatoid synovitis of the knee (1994)
    Springer
    Clinical rheumatology 13 (1994), S. 103-109 
    Details
    ISSN: 1434-9949
    Keywords: Rheumatoid Arthritis ; Intra-articular Injection ; Rimexolone ; Clinical Trial ; Pharmacokinetics ; Pharmacodynamics
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Twenty patients with classical or definite rheumatoid arthritis received one intra-articular injection of 40, 80, 120, 160 or 200 mg rimexolone (Org 6216) into one knee joint. Rimexolone was well tolerated and the incidence of side-effects was low. A beneficial effect was sustained over the study period of 94 days and a long-lasting effect was observed in 84% of the patients after one year and in 79% after 2 years. Safety parameters remained unaffected. Individual changes in adrenal response to ACTH and morning cortisol levels did not correlate with the dose or with serum levels of rimexolone. Rimexolone showed linear kinetics. The mean residence time in the intra-articular depot was 44 days (SD±53) with a median of 26 days. Ninety percent was absorbed after 4 months. Outside the intra-articular depot the mean residence time was less than 0.1 days.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF02229875
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...